Taken together, we argue that a pharmacological intervention with RAC1 inhibitor (or its downstream effectors) in combination with anti-PD-L1/PD-1 antibody may provide a novel therapeutic opportunity in BRAF inhibitor-resistant melanoma patients. The gene discussed is BRAF; the disease is melanoma.